Publication Results

Generate Report

Add publications by marking their checkboxes, or

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).

Crew KD,  Anderson GL,  Hershman DL,  Terry MB,  Tehranifar P,  Lew DL,  Yee M,  Brown EA,  Kairouz SS,  Kuwajerwala N,  Bevers T,  Doster JE,  Zarwan C,  Kruper L,  Minasian LM,  Ford L,  Arun B,  Neuhouser M,  Goodman GE,  Brown PH
Cancer Prev Res (Phila) 2019 Jul;12(7):481-490
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 31138522
PMC ID: PMC6609474

Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer.

Samimi G,  Heckman-Stoddard BM,  Kay SS,  Bloodgood B,  Coa KI,  Robinson JL,  Tennant B,  Ford LG,  Szabo E,  Minasian L
Cancer Prev Res (Phila) 2019 Apr;12(4):271-282
Major Program(s) or Research Group(s): Breast and Gynecologic CancerLung and Upper Aerodigestive Cancer ;  Office of the Director
PubMed ID: 30824471
PMC ID: PMC6445710

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

Goodman PJ,  Tangen CM,  Darke AK,  Lucia MS,  Ford LG,  Minasian LM,  Parnes HL,  LeBlanc ML,  Thompson IM Jr
N Engl J Med 2019 Jan 24;380(4):393-394
Major Program(s) or Research Group(s): NCI Community Oncology Research Program ;  Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 30673548
PMC ID: not available

Repurposing metformin for the prevention of cancer and cancer recurrence.

Heckman-Stoddard BM,  DeCensi A,  Sahasrabuddhe VV,  Ford LG
Diabetologia 2017 Sep;60(9):1639-1647
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 28776080
PMC ID: PMC5709147

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

McCaskill-Stevens W,  Pearson DC,  Kramer BS,  Ford LG,  Lippman SM
Cancer Prev Res (Phila) 2017 Feb;10(2):99-107
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 27965286
PMC ID: PMC5292088

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK,  Steele VE,  Fagerstrom RM,  Topp CF,  Ransohoff D,  Cunningham C,  Lubet R,  Ford LG,  Kramer BS
J Natl Cancer Inst 2015 Dec;107(12):djv259
Major Program(s) or Research Group(s): BiometryChemopreventive Agent Development ;  Office of the Director
PubMed ID: 26420882
PMC ID: PMC4862414

Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo).

Apolo Andrea Borghese,  Lee Min-Jung,  Tomita Yusuke,  Lee Sunmin,  Agarwal Piyush K.,  Jackson Gloria,  Francis Deneise C.,  Lamping Elizabeth,  Buford Lauren,  Tomita Saori,  Mackall Katherine,  Parnes Howard L.,  Dahut William L.,  Gulley James L.,  Trepel Jane B.
J Clin Oncol 2015 May 20;33(15):Abstract e15501
Major Program(s) or Research Group(s): Prostate and Urologic Cancer
PubMed ID: not available
PMC ID: not available

SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac): A randomized, double-blind, placebo-controlled phase III clinical trial.

Zell Jason A.,  Unger Joseph M.,  Anderson Garnet L.,  Cook Elise D.,  Krouse Robert S.,  Lance M. Peter,  Minasian Lori M.,  Ford Leslie,  Brown Powel
J Clin Oncol 2015 May 20;33(15):Abstract TPS3627
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: not available
PMC ID: not available

Estimates of benefits and harms of prophylactic use of aspirin in the general population.

Cuzick J,  Thorat MA,  Bosetti C,  Brown PH,  Burn J,  Cook NR,  Ford LG,  Jacobs EJ,  Jankowski JA,  La Vecchia C,  Law M,  Meyskens F,  Rothwell PM,  Senn HJ,  Umar A
Ann Oncol 2015 Jan;26(1):47-57
Major Program(s) or Research Group(s): Gastrointestinal and Other CancersLung and Upper Aerodigestive Cancer ;  Office of the Director
PubMed ID: 25096604
PMC ID: PMC4269341

Prevention and early detection of prostate cancer.

Cuzick J,  Thorat MA,  Andriole G,  Brawley OW,  Brown PH,  Culig Z,  Eeles RA,  Ford LG,  Hamdy FC,  Holmberg L,  Ilic D,  Key TJ,  La Vecchia C,  Lilja H,  Marberger M,  Meyskens FL,  Minasian LM,  Parker C,  Parnes HL,  Perner S,  Rittenhouse H,  Schalken J,  Schmid HP,  Schmitz-Dräger BJ,  Schröder FH,  Stenzl A,  Tombal B,  Wilt TJ,  Wolk A
Lancet Oncol 2014 Oct;15(11):e484-92
Major Program(s) or Research Group(s): Early DetectionLung and Upper Aerodigestive Cancer ;  Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 25281467
PMC ID: PMC4203149

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Gandini S,  Puntoni M,  Heckman-Stoddard BM,  Dunn BK,  Ford L,  DeCensi A,  Szabo E
Cancer Prev Res (Phila) 2014 Sep;7(9):867-85
Major Program(s) or Research Group(s): Breast and Gynecologic CancerChemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 24985407
PMC ID: PMC4154969

Phase III prostate cancer chemoprevention trials.

Parnes HL,  Brawley OW,  Minasian LM,  Ford LG
Recent Results Cancer Res 2014;202:73-7
Major Program(s) or Research Group(s): Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 24531780
PMC ID: not available

Results of the two incidence screenings in the National Lung Screening Trial.

Aberle DR,  DeMello S,  Berg CD,  Black WC,  Brewer B,  Church TR,  Clingan KL,  Duan F,  Fagerstrom RM,  Gareen IF,  Gatsonis CA,  Gierada DS,  Jain A,  Jones GC,  Mahon I,  Marcus PM,  Rathmell JM,  Sicks J,  National Lung Screening Trial Research Team
N Engl J Med 2013 Sep 5;369(10):920-31
Major Program(s) or Research Group(s): BiometryNutritional Science
PubMed ID: 24004119
PMC ID: PMC4307922

Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr,  Goodman PJ,  Tangen CM,  Parnes HL,  Minasian LM,  Godley PA,  Lucia MS,  Ford LG
N Engl J Med 2013 Aug 15;369(7):603-10
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 23944298
PMC ID: PMC4141537
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

Visvanathan K,  Hurley P,  Bantug E,  Brown P,  Col NF,  Cuzick J,  Davidson NE,  Decensi A,  Fabian C,  Ford L,  Garber J,  Katapodi M,  Kramer B,  Morrow M,  Parker B,  Runowicz C,  Vogel VG 3rd,  Wade JL,  Lippman SM
J Clin Oncol 2013 Aug 10;31(23):2942-62
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer
PubMed ID: 23835710
PMC ID: not available

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Cuzick J,  Sestak I,  Bonanni B,  Costantino JP,  Cummings S,  DeCensi A,  Dowsett M,  Forbes JF,  Ford L,  LaCroix AZ,  Mershon J,  Mitlak BH,  Powles T,  Veronesi U,  Vogel V,  Wickerham DL,  SERM Chemoprevention of Breast Cancer Overview Group
Lancet 2013 May 25;381(9880):1827-34
Major Program(s) or Research Group(s): Lung and Upper Aerodigestive CancerCommunity Oncology and Prevention TrialsNCI Community Oncology Research Program
PubMed ID: 23639488
PMC ID: PMC3671272
Clinical Trials: Breast Cancer Prevention Trial (BCPT) ;  Study of Tamoxifen and Raloxifene (STAR)

Exemestane for breast cancer prevention: a critical shift?

Decensi A,  Dunn BK,  Puntoni M,  Gennari A,  Ford LG
Cancer Discov 2012 Jan;2(1):25-40
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 22585166
PMC ID: PMC3354700

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

Runowicz CD,  Costantino JP,  Wickerham DL,  Cecchini RS,  Cronin WM,  Ford LG,  Vogel VG,  Wolmark N
Am J Obstet Gynecol 2011 Dec;205(6):535.e1-5
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Office of the Director
PubMed ID: 21872200
PMC ID: PMC5160016
Clinical Trials: Study of Tamoxifen and Raloxifene (STAR)

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C,  Tang G,  Pogue-Geile KL,  Costantino JP,  Baehner FL,  Baker J,  Cronin MT,  Watson D,  Shak S,  Bohn OL,  Fumagalli D,  Taniyama Y,  Lee A,  Reilly ML,  Vogel VG,  McCaskill-Stevens W,  Ford LG,  Geyer CE Jr,  Wickerham DL,  Wolmark N,  Paik S
J Clin Oncol 2011 Nov 1;29(31):4160-7
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Office of the Director
PubMed ID: 21947828
PMC ID: PMC3208536
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA,  Thompson IM Jr,  Tangen CM,  Crowley JJ,  Lucia MS,  Goodman PJ,  Minasian LM,  Ford LG,  Parnes HL,  Gaziano JM,  Karp DD,  Lieber MM,  Walther PJ,  Klotz L,  Parsons JK,  Chin JL,  Darke AK,  Lippman SM,  Goodman GE,  Meyskens FL Jr,  Baker LH
JAMA 2011 Oct 12;306(14):1549-56
Major Program(s) or Research Group(s): Office of the Director ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer ;  Community Clinical Oncology Program
PubMed ID: 21990298
PMC ID: PMC4169010
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Reduced lung-cancer mortality with low-dose computed tomographic screening.

National Lung Screening Trial Research Team,  Aberle DR,  Adams AM,  Berg CD,  Black WC,  Clapp JD,  Fagerstrom RM,  Gareen IF,  Gatsonis C,  Marcus PM,  Sicks JD
N Engl J Med 2011 Aug 4;365(5):395-409
Major Program(s) or Research Group(s): BiometryNutritional Science
PubMed ID: 21714641
PMC ID: PMC4356534

Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.

Jordan VC,  Ford LG
Cancer Prev Res (Phila) 2011 May;4(5):633-7
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 21478501
PMC ID: PMC3100896

Community Clinical Oncology Program & Minority Based-Community Clinical Oncology Program Accomplishments in Cancer Clinical Trials.

Kaluzny AD,  Weiner B,  Carpenter WR,  Greenwald P,  Ford LG,  Community Oncology and Prevention Trials Research Group
2011 January
View PDF
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials

The National Lung Screening Trial: overview and study design.

National Lung Screening Trial Research Team,  Aberle DR,  Berg CD,  Black WC,  Church TR,  Fagerstrom RM,  Galen B,  Gareen IF,  Gatsonis C,  Goldin J,  Gohagan JK,  Hillman B,  Jaffe C,  Kramer BS,  Lynch D,  Marcus PM,  Schnall M,  Sullivan DC,  Sullivan D,  Zylak CJ
Radiology 2011 Jan;258(1):243-53
Major Program(s) or Research Group(s): BiometryNutritional Science
PubMed ID: 21045183
PMC ID: PMC3009383

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Chlebowski RT,  Anderson GL,  Gass M,  Lane DS,  Aragaki AK,  Kuller LH,  Manson JE,  Stefanick ML,  Ockene J,  Sarto GE,  Johnson KC,  Wactawski-Wende J,  Ravdin PM,  Schenken R,  Hendrix SL,  Rajkovic A,  Rohan TE,  Yasmeen S,  Prentice RL,  WHI Investigators
JAMA 2010 Oct 20;304(15):1684-92
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 20959578
PMC ID: PMC5142300

Breast cancer prevention trials: large and small trials.

Arun B,  Dunn BK,  Ford LG,  Ryan A
Semin Oncol 2010 Aug;37(4):367-83
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20816507
PMC ID: not available

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG,  Costantino JP,  Wickerham DL,  Cronin WM,  Cecchini RS,  Atkins JN,  Bevers TB,  Fehrenbacher L,  Pajon ER,  Wade JL 3rd,  Robidoux A,  Margolese RG,  James J,  Runowicz CD,  Ganz PA,  Reis SE,  McCaskill-Stevens W,  Ford LG,  Jordan VC,  Wolmark N,  National Surgical Adjuvant Breast and Bowel Project
Cancer Prev Res (Phila) 2010 Jun;3(6):696-706
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Community Clinical Oncology Program
PubMed ID: 20404000
PMC ID: PMC2935331
Clinical Trials: Study of Tamoxifen and Raloxifene (STAR)

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Dunn BK,  Richmond ES,  Minasian LM,  Ryan AM,  Ford LG
Nutr Cancer 2010;62(7):896-918
Major Program(s) or Research Group(s): Gastrointestinal and Other CancersChemopreventive Agent Development ;  Community Clinical Oncology Program ;  Prostate and Urologic CancerCommunity Oncology and Prevention Trials
PubMed ID: 20924966
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.

Chlebowski RT,  Schwartz AG,  Wakelee H,  Anderson GL,  Stefanick ML,  Manson JE,  Rodabough RJ,  Chien JW,  Wactawski-Wende J,  Gass M,  Kotchen JM,  Johnson KC,  O'Sullivan MJ,  Ockene JK,  Chen C,  Hubbell FA,  Women's Health Initiative Investigators
Lancet 2009 Oct 10;374(9697):1243-51
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 19767090
PMC ID: PMC2995490

Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women.

Kabat GC,  Kim M,  Adams-Campbell LL,  Caan BJ,  Chlebowski RT,  Neuhouser ML,  Shikany JM,  Rohan TE,  WHI Investigators
Am J Clin Nutr 2009 Jul;90(1):162-9
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 19474140
PMC ID: PMC3987813

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM,  Klein EA,  Goodman PJ,  Lucia MS,  Thompson IM,  Ford LG,  Parnes HL,  Minasian LM,  Gaziano JM,  Hartline JA,  Parsons JK,  Bearden JD 3rd,  Crawford ED,  Goodman GE,  Claudio J,  Winquist E,  Cook ED,  Karp DD,  Walther P,  Lieber MM,  Kristal AR,  Darke AK,  Arnold KB,  Ganz PA,  Santella RM,  Albanes D,  Taylor PR,  Probstfield JL,  Jagpal TJ,  Crowley JJ,  Meyskens FL Jr,  Baker LH,  Coltman CA Jr
JAMA 2009 Jan 7;301(1):39-51
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 19066370
PMC ID: PMC3682779
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention.

Dunn BK,  Ryan A,  Ford LG
Recent Results Cancer Res 2009;181:183-93
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer
PubMed ID: 19213568
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

The use of tamoxifen and raloxifene for the prevention of breast cancer.

Wickerham DL,  Costantino JP,  Vogel VG,  Cronin WM,  Cecchini RS,  Ford LG,  Wolmark N
Recent Results Cancer Res 2009;181:113-9
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 19213563
PMC ID: PMC5110043

Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study.

Cauley JA,  Wampler NS,  Barnhart JM,  Wu L,  Allison M,  Chen Z,  Hendrix S,  Robbins J,  Jackson RD,  Women's Health Initiative Observational Study
Osteoporos Int 2008 Dec;19(12):1717-23
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18629572
PMC ID: PMC2663802

Calcium plus vitamin D supplementation and the risk of breast cancer.

Chlebowski RT,  Johnson KC,  Kooperberg C,  Pettinger M,  Wactawski-Wende J,  Rohan T,  Rossouw J,  Lane D,  O'Sullivan MJ,  Yasmeen S,  Hiatt RA,  Shikany JM,  Vitolins M,  Khandekar J,  Hubbell FA,  Women's Health Initiative Investigators
J Natl Cancer Inst 2008 Nov 19;100(22):1581-91
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 19001601
PMC ID: PMC2673920

Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial.

Ritenbaugh C,  Stanford JL,  Wu L,  Shikany JM,  Schoen RE,  Stefanick ML,  Taylor V,  Garland C,  Frank G,  Lane D,  Mason E,  McNeeley SG,  Ascensao J,  Chlebowski RT,  Women's Health Initiative Investigators
Cancer Epidemiol Biomarkers Prev 2008 Oct;17(10):2609-18
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18829444
PMC ID: PMC2937217

Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative.

Chen Z,  Arendell L,  Aickin M,  Cauley J,  Lewis CE,  Chlebowski R,  Women's Health Initiative Program, National Heart, Lung and Blood Institute, US Department of Health and Human Services
Cancer 2008 Sep 1;113(5):907-15
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18666209
PMC ID: PMC2909006

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Lucia MS,  Darke AK,  Goodman PJ,  La Rosa FG,  Parnes HL,  Ford LG,  Coltman CA Jr,  Thompson IM
Cancer Prev Res (Phila) 2008 Aug;1(3):167-73
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Prostate and Urologic Cancer ;  Community Clinical Oncology Program
PubMed ID: 19138952
PMC ID: PMC3985428
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Estimating rates of true high-grade disease in the prostate cancer prevention trial.

Pinsky P,  Parnes H,  Ford L
Cancer Prev Res (Phila) 2008 Aug;1(3):182-6
Major Program(s) or Research Group(s): Early Detection ;  Office of the Director ;  Prostate and Urologic CancerCommunity Oncology and Prevention Trials ;  Community Clinical Oncology Program
PubMed ID: 19138954
PMC ID: not available

Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.

Chlebowski RT,  Anderson G,  Pettinger M,  Lane D,  Langer RD,  Gilligan MA,  Walsh BW,  Chen C,  McTiernan A,  Women's Health Initiative Investigators
Arch Intern Med 2008 Feb 25;168(4):370-7; quiz 345
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18299491
PMC ID: not available

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS,  Epstein JI,  Goodman PJ,  Darke AK,  Reuter VE,  Civantos F,  Tangen CM,  Parnes HL,  Lippman SM,  La Rosa FG,  Kattan MW,  Crawford ED,  Ford LG,  Coltman CA Jr,  Thompson IM
J Natl Cancer Inst 2007 Sep 19;99(18):1375-83
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 17848673
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.

Dunn BK,  Ford LG
Eur J Cancer Prev 2007 Jun;16(3):232-42
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 17415094
PMC ID: not available

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG,  Costantino JP,  Wickerham DL,  Cronin WM,  Cecchini RS,  Atkins JN,  Bevers TB,  Fehrenbacher L,  Pajon ER Jr,  Wade JL 3rd,  Robidoux A,  Margolese RG,  James J,  Lippman SM,  Runowicz CD,  Ganz PA,  Reis SE,  McCaskill-Stevens W,  Ford LG,  Jordan VC,  Wolmark N,  National Surgical Adjuvant Breast and Bowel Project (NSABP)
JAMA 2006 Jun 21;295(23):2727-41
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Office of the Director ;  Community Clinical Oncology Program
PubMed ID: 16754727
PMC ID: not available
Clinical Trials: Study of Tamoxifen and Raloxifene (STAR)

The prostate cancer prevention trial: design, biases and interpretation of study results.

Goodman PJ,  Thompson IM Jr,  Tangen CM,  Crowley JJ,  Ford LG,  Coltman CA Jr
J Urol 2006 Jun;175(6):2234-42
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Community Clinical Oncology Program ;  Prostate and Urologic Cancer
PubMed ID: 16697846
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.

Prentice RL,  Caan B,  Chlebowski RT,  Patterson R,  Kuller LH,  Ockene JK,  Margolis KL,  Limacher MC,  Manson JE,  Parker LM,  Paskett E,  Phillips L,  Robbins J,  Rossouw JE,  Sarto GE,  Shikany JM,  Stefanick ML,  Thomson CA,  Van Horn L,  Vitolins MZ,  Wactawski-Wende J,  Wallace RB,  Wassertheil-Smoller S,  Whitlock E,  Yano K,  Adams-Campbell L,  Anderson GL,  Assaf AR,  Beresford SA,  Black HR,  Brunner RL,  Brzyski RG,  Ford L,  Gass M,  Hays J,  Heber D,  Heiss G,  Hendrix SL,  Hsia J,  Hubbell FA,  Jackson RD,  Johnson KC,  Kotchen JM,  LaCroix AZ,  Lane DS,  Langer RD,  Lasser NL,  Henderson MM
JAMA 2006 Feb 8;295(6):629-42
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 16467232
PMC ID: not available

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B,  Costantino JP,  Wickerham DL,  Cecchini RS,  Cronin WM,  Robidoux A,  Bevers TB,  Kavanah MT,  Atkins JN,  Margolese RG,  Runowicz CD,  James JM,  Ford LG,  Wolmark N
J Natl Cancer Inst 2005 Nov 16;97(22):1652-62
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Community Clinical Oncology Program
PubMed ID: 16288118
PMC ID: not available
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Estimated impact of the Prostate Cancer Prevention Trial on population mortality.

Unger JM,  Thompson IM Jr,  LeBlanc M,  Crowley JJ,  Goodman PJ,  Ford LG,  Coltman CA Jr
Cancer 2005 Apr 1;103(7):1375-80
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer ;  Office of the Director
PubMed ID: 15739207
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM,  Goodman PJ,  Klein EA,  Parnes HL,  Thompson IM Jr,  Kristal AR,  Santella RM,  Probstfield JL,  Moinpour CM,  Albanes D,  Taylor PR,  Minasian LM,  Hoque A,  Thomas SM,  Crowley JJ,  Gaziano JM,  Stanford JL,  Cook ED,  Fleshner NE,  Lieber MM,  Walther PJ,  Khuri FR,  Karp DD,  Schwartz GG,  Ford LG,  Coltman CA Jr
J Natl Cancer Inst 2005 Jan 19;97(2):94-102
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Prostate and Urologic Cancer ;  Community Clinical Oncology Program
PubMed ID: 15657339
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Prevention of hormone-related cancers: breast cancer.

Dunn BK,  Wickerham DL,  Ford LG
J Clin Oncol 2005 Jan 10;23(2):357-67
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 15637398
PMC ID: not available

Prevention of hormone-related cancers: prostate cancer.

Parnes HL,  Thompson IM,  Ford LG
J Clin Oncol 2005 Jan 10;23(2):368-77
Major Program(s) or Research Group(s): Prostate and Urologic Cancer
PubMed ID: 15637399
PMC ID: not available

Delivering prostate cancer prevention messages to the public: how the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results.

Croker KS,  Ryan A,  Morzenti T,  Cave L,  Maze-Gallman T,  Ford L
Urol Oncol 2004 Jul-Aug;22(4):369-76
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 15283899
PMC ID: not available

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM,  Pauler DK,  Goodman PJ,  Tangen CM,  Lucia MS,  Parnes HL,  Minasian LM,  Ford LG,  Lippman SM,  Crawford ED,  Crowley JJ,  Coltman CA Jr
N Engl J Med 2004 May 27;350(22):2239-46
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer ;  Office of the Director
PubMed ID: 15163773
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Implementation of the Prostate Cancer Prevention Trial (PCPT).

Goodman PJ,  Tangen CM,  Crowley JJ,  Carlin SM,  Ryan A,  Coltman CA Jr,  Ford LG,  Thompson IM
Control Clin Trials 2004 Apr;25(2):203-22
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer ;  Office of the Director
PubMed ID: 15020037
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

The influence of finasteride on the development of prostate cancer.

Thompson IM,  Goodman PJ,  Tangen CM,  Lucia MS,  Miller GJ,  Ford LG,  Lieber MM,  Cespedes RD,  Atkins JN,  Lippman SM,  Carlin SM,  Ryan A,  Szczepanek CM,  Crowley JJ,  Coltman CA Jr
N Engl J Med 2003 Jul 17;349(3):215-24
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer
PubMed ID: 12824459
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Prevention and early detection clinical trials: opportunities for primary care providers and their patients.

Ford LG,  Minasian LM,  McCaskill-Stevens W,  Pisano ED,  Sullivan D,  Smith RA
CA Cancer J Clin 2003 Mar-Apr;53(2):82-101
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 12691266
PMC ID: not available

How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Sateren WB,  Trimble EL,  Abrams J,  Brawley O,  Breen N,  Ford L,  McCabe M,  Kaplan R,  Smith M,  Ungerleider R,  Christian MC
J Clin Oncol 2002 Apr 15;20(8):2109-17
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 11956272
PMC ID: not available

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

King MC,  Wieand S,  Hale K,  Lee M,  Walsh T,  Owens K,  Tait J,  Ford L,  Dunn BK,  Costantino J,  Wickerham L,  Wolmark N,  Fisher B,  National Surgical Adjuvant Breast and Bowel Project
JAMA 2001 Nov 14;286(18):2251-6
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Community Clinical Oncology Program
PubMed ID: 11710890
PMC ID: not available
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Breast cancer prevention: the next steps.

Dunn BK,  McCaskill-Stevens W,  Ford LG
Eur J Cancer 2000 Sep;36 Suppl 4:S53-4
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentCommunity Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 11056319
PMC ID: not available

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B,  Costantino JP,  Wickerham DL,  Redmond CK,  Kavanah M,  Cronin WM,  Vogel V,  Robidoux A,  Dimitrov N,  Atkins J,  Daly M,  Wieand S,  Tan-Chiu E,  Ford L,  Wolmark N
J Natl Cancer Inst 1998 Sep 16;90(18):1371-88
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Community Clinical Oncology Program
PubMed ID: 9747868
PMC ID: not available
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Community Clinical Oncology Program participation in the Breast Cancer Prevention Trial: factors affecting accrual.

Klabunde C,  Kaluzny A,  Ford L
Cancer Epidemiol Biomarkers Prev 1995 Oct-Nov;4(7):783-9
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 8672997
PMC ID: not available

The community clinical oncology program: its effect on clinical practice.

Warnecke RB,  Johnson TP,  Kaluzny AD,  Ford LG
Jt Comm J Qual Improv 1995 Jul;21(7):336-9
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 7581736
PMC ID: not available

Design of the Prostate Cancer Prevention Trial (PCPT).

Feigl P,  Blumenstein B,  Thompson I,  Crowley J,  Wolf M,  Kramer BS,  Coltman CA Jr,  Brawley OW,  Ford LG
Control Clin Trials 1995 Jun;16(3):150-63
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer
PubMed ID: 7540965
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.

Kaluzny A,  Brawley O,  Garson-Angert D,  Shaw J,  Godley P,  Warnecke R,  Ford L
J Natl Cancer Inst 1993 Dec 1;85(23):1945-50
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Community Clinical Oncology Program
PubMed ID: 8230286
PMC ID: not available